Genomic alterations in ALK are found in numerous malignancies 1 . In a phase 1 trial, the ALK TKI crizotinib induced an objective radiographic response (ORR) of 60.8% and a median progression-free survival of 9.7 months in patients with ALK fusion-positive (ALK + ) lung cancer 2 . Unfortunately, patients invariably developed therapeutic resistance. The mechanisms of resistance to ALK blockade are only beginning to be elucidated 3-6 .
a r t i c l e s 1 0 2 8 VOLUME 20 | NUMBER 9 | SEPTEMBER 2014 nature medicine She remained on this treatment longer than any other patient enrolled in the trial. At the time of progression on erlotinib plus the IGF-1R mAb, the patient's tumor was sent for molecular profiling. As expected based on the lack of response to erlotinib, the tumor did not contain an EGFR mutation ( Supplementary Table 1) ; surprisingly, however, it did harbor an ALK rearrangement. Subsequently, this patient enrolled in the phase 3 trial of crizotinib compared to chemotherapy (profile 1007, NCT00932893) and was randomized to pemetrexed, a folate antimetabolite. After four cycles, she had disease progression ( Fig. 1d,e ), started on crizotinib per the trial protocol and had a partial response (Fig. 1f) .
Previous studies have reported a 0% response rate for patients with ALK + lung cancer treated with erlotinib alone 8 . Thus, we hypothesized that in this patient, either the combination of erlotinib plus the IGF-1R inhibitor was synergistic against ALK + lung cancer or the IGF-1R inhibitor alone was somehow responsible for the tumor response. To address this hypothesis, we treated H3122 cells, which harbor an EML4-ALK E13;A20 fusion (where E13;A20 refers to the exons in EML4 (E) that are fused to ALK (A)), with erlotinib, an IGF-1R TKI or MAb alone Figure 1 Exceptional response to an IGF-1R inhibitor before ALK TKI therapy in a patient with ALK + lung cancer. Representative images from serial computed tomography scans of the chest of a 50-year-old female with ALK + lung cancer documenting responses to the therapies indicated. Images are labeled a-f in temporal sequence. The red circles in a-c represent a new lesion in the right lung that developed after 1 month of erlotinib and then responded to erlotinib plus an IGF-1R-specific antibody. The scale bar in Figure 1a indicates 4 cm and is representative for all images. Figs. 1i and 2b) . This experiment was repeated three independent times. npg or the combination. We observed no therapeutic synergism between erlotinib and the IGF-1R inhibitors ( Supplementary Fig. 1a,b) , suggesting that this patient's tumor response was more likely due to the IGF-1R-specific antibody. On the basis of this clinical observation, we hypothesized that there is crosstalk between IGF-1R and ALK that may be exploited therapeutically to improve antitumor responses.
Therapeutic synergism between ALK and IGF-1R inhibitors
We tested the ability of IGF-1R inhibitors alone or in combination with ALK inhibitors to impede the growth of ALK + lung cancer cell lines. The IGF-1R-specific mAb, mAb391, had modest but reproducible single-agent activity in H3122 cells. However, mAb391 sensitized H3122 cells to the antiproliferative effects of crizotinib ( Fig. 2a) .
When we inhibited IGF-1R with mAb391, sensitivity to crizotinib was also enhanced in STE-1 (EML4-ALK E13;A20) cells, a new lung adenocarcinoma cell line that we developed from a patient with ALK + lung cancer ( Supplementary Fig. 1c ). We observed similar results when we treated H3122 cells with the dual IGF-1R and insulin receptor TKI OSI-906 plus crizotinib ( Fig. 2b) . We extended this finding to other ALK + lung cancer cell lines, including H2228 (EML4-ALK E6a/b;A20) ( Fig. 2c ) and STE-1 ( Fig. 2d ). Co-treatment with an ALK TKI plus an IGF-1R TKI also induced better antitumor responses in SUDHL-1 lymphoma cells, which harbor an NPM-ALK fusion, suggesting that this effect is not specific to ALK-mutant lung cancer cells ( Supplementary Fig. 1e ). We confirmed the combination of crizotinib plus OSI-906 to be synergistic using the Mix-Low method 9 , which is a standard mathematical model to assess drug-drug interactions ( Supplementary Fig. 1d ). OSI-906 has no off-target activity against ALK at the doses used in these experiments 10 .
Compared to crizotinib alone, the combination of crizotinib plus OSI-906 resulted in increased levels of apoptosis ( Fig. 2e ) and decreased phosphorylation of downstream targets ( Fig. 2f) . Furthermore, the combination of crizotinib plus mAb391 was more effective at delaying the growth of ALK + xenografts in nude (nu/nu) mice ( Supplementary Fig. 1f ). Collectively these data show that the combination of ALK plus IGF-1R inhibitors results in an enhanced antiproliferative response in ALK + lung cancer cells.
To ascertain the specificity of this effect, we examined whether inhibitors of other tyrosine kinases could produce analogous results. Neither the epidermal growth factor receptor (EGFR) inhibitor erlotinib ( Supplementary Fig. 1g ) nor the dual HER2 (also called ERBB2) and EGFR inhibitor lapatinib ( Supplementary Fig. 1h ) was able to sensitize H3122 cells to the effects of crizotinib. These data suggest that the synergistic antiproliferative effect described above is specific to IGF-1R blockade.
To assess whether ligand-induced activation of IGF-1R could influence the antiproliferative effects of ALK blockade, we treated H3122 cells with crizotinib alone or in combination with IGF-1. The addition of IGF-1 induced resistance to the growth-inhibitory effects of crizotinib ( Fig. 3a) . IGF-1 ligand stimulated phosphorylation of IGF-1R but not ALK ( Fig. 3b and Supplementary Fig. 2a ), suggesting no direct crosstalk between the two kinases. When we stimulated cells pretreated with crizotinib with IGF-1, ALK phosphorylation was inhibited; however, downstream signaling was sustained, as evidenced by continued phosphorylation of AKT ( Fig. 3b ). OSI-906 was able to inhibit this response. Taken together, these data suggest that signaling through IGF-1R may be a compensatory mechanism for the growthinhibitory effects of ALK inhibitor therapy. Immunoblot analysis using antibodies specific to the proteins indicated of lysates from H3122 cells that were serum starved overnight and then treated with the indicated TKIs for 6 h, followed by stimulation with IGF-1 for 10 min. This experiment was repeated independently three times. (c) Immunoprecipitation (IP) of IRS-1 and western blotting for the indicated proteins using lysates from H3122 cells that were treated with vehicle or crizotinib. (d) IP for IRS-1 and western blot for the indicated proteins derived from pulverized and lysed tumor-containing lung tissue from two different EML4-ALK E13;A20 transgenic mice. (e) Immunoblotting using antibodies specific for the proteins indicated from STE-1 cells that were transfected with the nontargeting siRNA (NT) or with two distinct pools from IRS-1 siRNA and treated with 500 nM crizotinib for 72 h. 
IRS-1 knockdown impedes growth of ALK + lung cancer cells
We investigated the molecular mechanisms underlying the cooperative antitumor response between ALK and IGF-1R inhibitors. IRS-1 is a well-known substrate and adaptor protein for IGF-1R 11 , and IRS-1 has been demonstrated to be a primary adaptor for phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) activation in H3122 cells 12 . However, the precise mechanism by which ALK fusion proteins link to effector pathways remains undefined. We observed that IRS-1 levels decreased with crizotinib treatment (Fig. 3b ). Using lysates from H3122 cells, we found that ALK and IRS-1 coimmunoprecipitated and that the interaction decreased after the addition of crizotinib ( Fig. 3c) . We also validated that this interaction occurs in vivo using lung tumor tissue from two different EML4-ALK E13;A20 transgenic mice 13 (Fig. 3d) .
Next we hypothesized that if IRS-1 is an adaptor protein for ALK, then knockdown of IRS-1 would sensitize cells to the effects of ALK inhibition. Consistent with our hypothesis, IRS-1 knockdown sensitized STE-1 cells to the effects of crizotinib (Fig. 3e) . The levels of phosphorylated AKT, S6 and ERK were lower in IRS-1 siRNAtransfected, crizotinib-treated cells compared to crizotinib-treated controls. IRS-1 knockdown impaired the proliferation of STE-1 cells in the absence of crizotinib and also sensitized these cells to the antiproliferative effects of ALK inhibition ( Fig. 3f,g) . We observed analogous results in H2228 cells ( Supplementary Fig. 3a,b) . Taken together, these data suggest that IRS-1 is an adaptor protein that links both IGF-1R and ALK to downstream signaling pathways.
IGF-1R pathway upregulation in ALK TKI-resistant cells
Our data suggest that increased signaling through IGF-1R, after stimulation with exogenous IGF-1 ligand, decreases cellular dependence on ALK, as indicated by diminished sensitivity to ALK TKIs (Fig. 3a,b) . Understanding the signaling of an oncogene can also help provide an npg understanding of how therapeutic resistance develops. We therefore modeled ALK TKI resistance in vitro. Starting with drug-sensitive (parental) cells, we derived H3122 cells that were resistant to crizotinib ( Fig. 4a) or to X-376 ( Fig. 4b) , which is a more potent and more specific ALK inhibitor 14 . Notably, a derivative of X-376 (X-396) is currently in phase 1 clinical trials in patients with advanced solid tumors (NCT01625234). We analyzed these resistant cell lines using a variety of methods. H3122 crizotinib-resistant (H3122 CR) cells displayed amplification of the EML4-ALK E13;A20 fusion by ALK fluorescence in situ hybridization (FISH) (Supplementary Fig. 4a,b) , as described previously 15 . These cells did not have any second-site ALK kinase domain mutations (data not shown).
H3122 X376-resistant (H3122 XR) cells harbored neither ALK amplification (Supplementary Fig. 4c ) nor second-site mutations. However, H3122 XR cells maintained phosphorylation of AKT, S6 and ERK even in the continued presence of X-376 ( Fig. 4c) . We hypothesized that an alternative upstream kinase(s) must be activated in these cells to maintain signaling. Phospho-receptor tyrosine kinase (RTK) arrays revealed an increase in IGF-1R phosphorylation (Supplementary Fig. 4d) . Indeed, IGF-1R phosphorylation and total protein levels were elevated in the ALK TKI-resistant compared to the ALK TKI-sensitive (i.e., parental) cells (Fig. 4c) . H3122 XR cells also exhibited increased phosphorylation and total protein levels of IRS-1. Overall these results suggest that the IGF-1R-IRS-1 pathway has a role in maintaining downstream signaling in the presence of continuous ALK inhibition and may therefore be a mechanism by which cells evade ALK blockade.
We next sought to determine how IGF-1 signaling is upregulated in ALK TKI-resistant cells. IGF-1 ligand levels were increased in the conditioned medium from H3122 XR cells (Supplementary Fig. 4d ). Gene expression profiling revealed that IGF binding protein 3 (IGFBP3) was downregulated in resistant compared to parental cells (Supplementary Tables 2 and 3) . IGFBP3 is known to block IGF-1induced activation of IGF-1R 16, 17 . Overall these studies show that the IGF-1R signaling pathway is activated by multiple mechanisms in H3122 XR cells.
We evaluated the effects of IGF-1R inhibition in ALK TKI-resistant cells. The combination of X-376 with either mAb391 or OSI-906 ( Fig. 4d,e ) partially restored X-376 sensitivity in H3122 XR cells. Apoptosis was also enhanced in H3122 XR cells treated with X-376 (Fig. 4f) . In accord with these data, combination treatment with ALK and IGF-1R inhibitors in H3122 XR cells inhibited AKT phosphorylation to a greater extent than treatment with either inhibitor alone (Fig. 4g) . The addition of OSI-906 also partially restored the sensitivity of H3122 CR cells to the growth-inhibitory effects of crizotinib (Supplementary Fig. 4c ).
Because IRS-1 levels were increased in H3122 XR cells (Fig. 4c) , we examined whether IRS-1 knockdown would also affect signaling and proliferation in the resistant cells ( Fig. 4h,i) . We transfected H3122 XR cells with IRS-1 or control siRNAs and then treated them with X-376. IRS-1 knockdown sensitized these cells to the antiproliferative effects of ALK inhibition ( Fig. 4h) and resulted in a further decline in the phosphorylation of downstream targets compared to X-376 treatment alone or IRS-1 knockdown alone (Fig. 4i) .
Previous studies have suggested that the IGF-1R pathway can drive EGFR inhibitor resistance 19, 20 . We tested the efficacy of combined EGFR and IGF-1R inhibition in four different isogenic pairs of EGFR TKI-sensitive and EGFR TKI-resistant cell lines 21, 22 ( Supplementary  Table 4 ). The addition of the IGF-1R TKI OSI-906 was not synergistic with the EGFR TKI erlotinib in any of these cells ( Supplementary  Fig. 5a-d) . Furthermore, in contrast to the ALK TKI-resistant cells, there was no increase in IGF-1R or IRS-1 levels in the EGFR TKIresistant cell lines (Supplementary Fig. 5e ). Therefore, because there was no therapeutic synergism between EGFR and IGF-1R inhibitors in EGFR-mutant lung cancer cell lines, these data suggest that the synergistic effects seen with the ALK and IGF-1R inhibitor combinations in the ALK cell lines are true differences.
Increased IGF-1R in tumor samples at the time of resistance
To validate the clinical implications of our in vitro findings, we evaluated the levels of phosphorylated IGF-1R (pIGF-1R) and IRS-1 in patient lung cancer biopsy samples. We examined three sets of paired tumor samples before and after crizotinib treatment, as well as two tumor samples after crizotinib treatment from five different patients, by immunohistochemistry (IHC) for pIGF-1R. These samples were then blindly evaluated by pathologists. As a control, we also performed pIGF-1R IHC on lung cancer tissue microarrays (representative examples are shown in Supplementary Fig. 6a-c) . Four of five tumor biopsies taken at the time of acquired resistance displayed increased levels of pIGF-1R (Fig. 5a) . For two of the paired tumor samples, we had sufficient tissue to examine IRS-1 levels by IHC (Fig. 5b) ; one sample after treatment (patient 2) had increased IRS-1 expression. We also assessed these five samples for ALK kinase domain mutations that are associated with crizotinib resistance ( Supplementary Table 5 ). Patient 4's tumor after crizotinib treatment harbored an ALK G1202R mutation in the kinase domain.
As an orthogonal approach, we performed mRNA expression analysis for IGF1R and IRS1 using NanoString 23 on matched patient samples and on isogenic pairs of ALK TKI-sensitive and ALK TKIresistant cell lines. In the one case with enough tissue available for analysis before and after treatment, IGF1R and IRS1 (Fig. 5c,d) mRNA levels were increased in the tumor sample after crizotinib treatment relative to the sample before treatment. We obtained similar results with the cell lines. In contrast, NanoString analysis of 11 matched pairs of EGFR-mutant lung tumor biopsies revealed no significant change in IRS-1 levels after EGFR TKI therapy ( Supplementary  Fig. 6d-f ), suggesting that the changes observed in IRS-1 were specific to ALK + lung cancer. Overall these data validate our preclinical findings, showing that levels of IGF-1R and IRS-1 can be increased after ALK TKI therapy in patient-derived samples.
LDK-378 inhibits phosphorylation of ALK and IGF-1R in vitro
The second-generation ALK TKI LDK-378 (ceritinib) has demonstrated a 56% ORR in patients with ALK + lung cancer who have progressed on crizotinib 24 . Yet only a minority of these patients had ALK alterations, suggesting the possibility of alternative bypass mechanisms that are sensitive to LDK-378. Notably, LDK-378 and the structurally related ALK inhibitor TAE-684 can inhibit both ALK and Figure 6 The second-generation ALK inhibitor LDK-378 blocks the phosphorylation of both ALK and IGF-1R. (a) Cell growth inhibition, assessed by cell titer blue assays, of H3122 lung cancer cells containing the EML4-ALK E13;A20 fusion that were treated with increasing amounts of crizotinib, LDK-378 or TAE-684 for 72 h. Each point represents hextuplicate biological replicates ± s.d. Data are presented as the percentage of viable cells compared to control (vehicle treatment only) cells and are representative of three or more independent experiments. (b) Tumor volumes, assessed every 3-4 days, in athymic nu/nu female mice that were injected subcutaneously with H3122 lung cancer cells harboring the EML4-ALK E13;A20 fusion. When tumors reached an average volume of 100 mm 3 , mice were randomized to receive crizotinib alone (50 mg per kg body weight by mouth (p.o.) daily for 5 d), LDK-378 alone (50 mg per kg body weight p.o. daily for 5 d) or vehicle control (n = 5 for crizotinib, and LDK-378, n = 4 for vehicle control). Data represent the mean tumor volume ± s.d. P = 0.0159 based on the Wilcoxon rank-sum test for the comparison between crizotinib and LDK-378. (c,d) Immunoblotting using antibodies specific for the proteins indicated of lysates from H3122 (c) and H2228 cells (d) that were grown overnight in the presence or absence of serum and then treated with LDK-378 for 1 h, followed by stimulation with IGF-1 for 10 min and harvesting. This experiment was repeated three independent times.
npg IGF-1R in vitro 25 . We hypothesized that the efficacy of LDK-378 may be due to this drug's ability to simultaneously block both ALK and IGF-1R. LDK-378 was more potent than crizotinib in H3122 (Fig. 6a) , STE-1 (Supplementary Fig. 7a ) and H3122 XR ( Supplementary  Fig. 7b ) cells. LDK-378 was also more potent at inducing apoptosis in H3122 cells (Supplementary Fig. 7c ). Furthermore, LDK-378 was significantly more effective at delaying the growth of H3122 xenografts compared to the equivalent dose of crizotinib (Fig. 6b) .
Next we tested LDK-378's ability to inhibit IGF-1R phosphorylation. We treated H3122 (Fig. 6c) and H2228 (Fig. 6d) cells with LDK-378 alone or in combination with IGF-1. Notably, LDK-378 treatment inhibited ALK phosphorylation and was also able to overcome the IGF-1 ligand-induced increase in IGF-1R phosphorylation in both ALK + cell lines (Fig. 6c,d) . These data suggest that the potency of LDK-378 in vivo may be due to this agent's combined ability to block both ALK and IGF-1R.
DISCUSSION
We report that ALK and IGF-1R inhibitors have cooperative antiproliferative effects. IGF-1R inhibitors sensitized ALK fusionpositive lung cancer cells to the effects of ALK inhibition. We observed therapeutic synergism between ALK and IGF-1R inhibitors in both ALK TKI-sensitive and ALK TKI-resistant settings. Chronic ALK inhibition was associated with enhanced IGF-1R signaling. The ALK TKI-resistant cells used numerous mechanisms to activate IGF-1R signaling. Notably, the addition of an IGF-1R inhibitor sensitized the resistant cells to the effects of ALK blockade.
We propose drug combinations co-targeting ALK and IGF-1R as a new therapeutic approach in patients with ALK + lung cancer. This rationally selected combination of targeted therapies should be effective in both ALK TKI-naive and ALK TKI-resistant settings. Our data may also explain in part the surprising 56% ORR for the second-generation ALK TKI LDK-378 in patients with ALK + lung cancer who had progressed on crizotinib 24 . As we observed responses to LDK-378 in both patients with and without second-site ALK mutations, the increased on-target potency of LDK-378 toward ALK is by itself not enough to explain all of the responses seen with this agent. We hypothesize that the potency of this agent is due to its ability to simultaneously inhibit both ALK and IGF-1R, and our in vitro experiments confirm that LDK-378 does inhibit phosphorylation of both ALK and IGF-1R. Further studies will be necessary to validate this hypothesis in clinical samples.
The mechanisms of acquired resistance to ALK inhibitors are just beginning to be understood. Target alterations in ALK have been found in only a minority of resistant tumors examined so far. Bypass signaling has also been reported [3] [4] [5] [6] . Notably, target alterations and bypass signaling do not appear to be mutually exclusive. One of the patients in our study had both an ALK G1202R mutation and increased pIGF-1R levels at the time of crizotinib resistance. Previous reports have also documented the co-occurrence of ALK kinase domain mutations with increased EGFR phosphorylation or focal KIT amplification in two separate patients with crizotinib resistance 3 . The frequency of the various ALK TKI resistance mechanisms and the degree to which the offtarget effects of the ALK TKI may dictate both clinical efficacy and also the mechanism of resistance remain to be more precisely defined.
In conclusion, provoked by observations from an exceptional responder, we have identified the IGF-1R-IRS-1 signaling axis as a potential therapeutic target in ALK + lung cancer. Because ALK is as an oncogenic driver in a growing number of hematologic and solid organ tumors, an improved understanding of ALK signaling, as well as the mechanisms of escape from ALK inhibition, may have direct therapeutic implications for other ALK-driven malignancies.
METhODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The whole-genome sequencing data from this study can be accessed at the NCBI Sequence Read Archive (SRA; http:// www.ncbi.nlm.nih.gov/sra) under accession number SRP044308 (tumor: SRR1514863, and blood: SRR1514948). The microarray data reported in this article have been deposited in NCBI's Gene Expression Omnibus (GEO) database at http://www.ncbi.nlm.nih. gov/geo (accession number GSE49508).
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
STE-1 cells all harbored the EML4-ALK E13;A20 (variant 1) fusion and that H2228 harbored the EML4-ALK E6a/b;A20 (variant 3) fusion. No kinase domain mutations were found in any of these cell lines compared with Homo sapiens mRNA for EML4-ALK E13;A20 variant 1 (GeneBank: AB274722.1).
RTK proteome array and IGF-1 ELISAs. Proteome Profiler Human
Phospho-RTK Array Kits (R&D Systems, ARY001B) and human IGF-1 Quantikine ELISA kits (R&D Systems, DG100) were processed according to manufacturer protocols. siRNA experiments. Cells were reverse transfected with siRNAs using the Lipofectamine RNAimax reagent (Life Technologies, Grand Island, NY, USA). Nontargeting and IRS-1 siRNAs pools were purchased from Dharmacon (Lafayette, CO, USA) and Santa-Cruz (Dallas, TX, USA).
NanoString nCounter analysis. NanoString nCounter analysis of RNA isolated from formalin-fixed and paraffin-embedded (FFPE) samples was performed as described previously 23 . The raw data were normalized to the nCounter system spike-in positive and negative controls in each sample. The normalized results are expressed as the relative mRNA level. The comparison between groups before and after treatment was performed by modified paired t test using the limma package.
FISH. Samples were tested for ALK rearrangements by FISH (Vysis ALK Break
Apart FISH Probe Kit) as described previously 30 .
Gene expression analysis. RNA from cell lines and controls was prepared, labeled and hybridized to the Illumina HT-12 array. For analysis, the sample probe profile data in the GeneSpring export format was transformed to the log 2 scale and normalized using the quantile method by applying the beadarray package 31 in BioConductor 2.11. Four duplicated samples were averaged to reduce the total sample size to nine across three groups. The comparison between drugsensitive and drug-resistant groups was performed using the limma package. The significantly changed probes were identified by moderated t statistics. The P values from moderated t tests were adjusted by Benjamini and Hochberg's method to control the false discovery rate. The microarray data reported in this article have been deposited in NCBI's Gene Expression Omnibus (GEO) database at http://www.ncbi.nlm.nih.gov/geo (accession number GSE49508).
Xenograft studies. Nude mice (nu/nu; Harlan Laboratories) were used for in vivo studies and were cared for in accordance with guidelines approved by the Memorial Sloan Kettering Cancer Center Institutional Animal Care and Use Committee (IACUC) and Research Animal Resource Center. 8-week-old female mice were injected subcutaneously with 5 million H3122 cells together with Matrigel. Once tumors reached an average volume of 100 mm 3 , mice were randomized to the different treatment cohorts. For the experiment presented in Supplementary Figure 1f , mice were randomized to receive either crizotinib alone, mAb391 alone, crizotinib plus mAb391 or vehicle control (n = 6 for vehicle alone, crizotinib and crizotinib plus mAb391; n = 5 for mAb391 only). Crizotinib was administered at 50 mg per kg body weight p.o. daily for 5 d. mAb391 was administered at 1 mg intraperitoneally (i.p.) every 3 d. For the experiment presented in Figure 6b , mice were randomized to receive crizotinib alone (50 mg per kg body weight p.o. daily for 5 d), LDK-378 alone (50 mg per kg body weight p.o. daily for 5 d) or vehicle control (n = 5 for crizotinib and LDK-378, n = 4 for vehicle control). Mice were observed daily throughout the treatment period for signs of morbidity and/or mortality. Tumors were measured twice weekly using calipers, and tumor volume was calculated using the formula length × width 2 × 0.52. Body weight was also assessed twice weekly. P values were determined with the Wilcoxon rank-sum test. EML4-ALK E13;A20 transgenic mice. Genetically engineered mice harboring the EML4-ALK E13;A20 fusion variant have been reported previously 13 . Three-month-old mice of both genders were used in the studies described. All animal treatment studies were reviewed and approved by the IACUC at the Dana-Farber Cancer Institute.
Tumor biopsy samples. All patient tumor biopsy samples were obtained under Institutional Review Board (IRB)-approved protocols (Vanderbilt University IRB# 050644, Memorial Sloan Kettering Cancer Center IRB #10-136, University Hospital of Cologne IRB #06037 and Peter MacCallum Cancer Center IRB#08/71). Written informed consent was obtained from all patients. All samples were deidentified, and protected health information was reviewed according to Health Insurance Portability and Accountability Act (HIPAA) guidelines. For the index patient's tumor, clinical genotyping was performed using the SNaPshot platform as described previously 32 .
Clinical trial information. The index patient was enrolled in a phase 1/2a clinical trial of erlotinib followed at progression by erlotinib plus the IGF-1R monoclonal antibody, MK-0646, in patients with recurrent non-small cell lung cancer (NCT00654420).
IHC.
Tumors were pathologically identified and classified according to World Health Organization guidelines. Briefly, 3-µm-thick sections of FFPE tumors were deparaffinized. For pIGF-1R staining, antigen retrieval was performed by boiling the section in citrate buffer at pH 6 for 25 min. For IRS-1 staining, no pretreatment was necessary. The primary antibodies used were as follows: pIGF-1R (Y1161) (Ab39398, 1:100, pH 6, Abcam Inc.) and IRS-1 (Ab40777, 1:100, Abcam Inc.). Corresponding secondary antibodies and detection kits were used (Enhancer: post antibody blocking for Bright Vision plus; Immuno Logic c-DPVB blocking and Polymer: Poly-HRP-GAM/R/R IgG; Immuno Logic c-DPVB999HRP, BrightVision+ cat #DPVB999HRP, ImmunoLogic, Duiven, the Netherlands, http://www.immunologic.nl) and stained on an automated stainer (LabVision Autostainer 480S, Thermo Scientific). Staining intensities were individually evaluated by three independent observers.
